Drug Trial News

RSS
Kitov Pharmaceuticals' KIT-302 drug candidate meets primary efficacy endpoint in Phase III clinical trial

Kitov Pharmaceuticals' KIT-302 drug candidate meets primary efficacy endpoint in Phase III clinical trial

Lupuzor may become first non-immunosuppressant therapy for lupus

Lupuzor may become first non-immunosuppressant therapy for lupus

ImmunoCellular partners with CBTC for ICT-107 phase 3 registrational trial in patients with glioblastoma

ImmunoCellular partners with CBTC for ICT-107 phase 3 registrational trial in patients with glioblastoma

Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Combination treatment provides effective one-two punch against prostate cancer

Combination treatment provides effective one-two punch against prostate cancer

NIAID scientists successfully test prime-boost H7N9 influenza vaccine concept in clinical trial

NIAID scientists successfully test prime-boost H7N9 influenza vaccine concept in clinical trial

Anastrozole drug effective in treating early form of breast cancer

Anastrozole drug effective in treating early form of breast cancer

Biogen begins ISIS-SOD1 Rx Phase 1/2 clinical study in patients with amyotrophic lateral sclerosis

Biogen begins ISIS-SOD1 Rx Phase 1/2 clinical study in patients with amyotrophic lateral sclerosis

Sangamo presents Phase 2 data from two ongoing clinical trials of SB-728-T for treatment of HIV/AIDS

Sangamo presents Phase 2 data from two ongoing clinical trials of SB-728-T for treatment of HIV/AIDS

Adjuvant chemotherapy not beneficial for patients with luminal A subtype of breast cancer

Adjuvant chemotherapy not beneficial for patients with luminal A subtype of breast cancer

Pathologic complete response after presurgery chemotherapy increases overall survival for TNBC patients

Pathologic complete response after presurgery chemotherapy increases overall survival for TNBC patients

Capecitabine increases disease-free survival for HER2-negative breast cancer patients

Capecitabine increases disease-free survival for HER2-negative breast cancer patients

Palatin achieves patient enrollment target in pivotal phase 3 studies of bremelanotide for FSD treatment

Palatin achieves patient enrollment target in pivotal phase 3 studies of bremelanotide for FSD treatment

Lilly, Merck announce another immuno-oncology collaboration

Lilly, Merck announce another immuno-oncology collaboration

Sinovac gets approval to begin clinical trials on Sabin Inactivated Polio Vaccine candidate

Sinovac gets approval to begin clinical trials on Sabin Inactivated Polio Vaccine candidate

Boehringer Ingelheim begins SENSCIS study to investigate safety, efficacy of nintedanib in patients with SSc-ILD

Boehringer Ingelheim begins SENSCIS study to investigate safety, efficacy of nintedanib in patients with SSc-ILD

Adjuvant denosumab improves disease-free survival for postmenopausal women with early-stage, HR+ breast cancer

Adjuvant denosumab improves disease-free survival for postmenopausal women with early-stage, HR+ breast cancer

Tetra begins human Phase 1 safety trials of BPN14770

Tetra begins human Phase 1 safety trials of BPN14770

RTFCCR grant supports ASCOLT study that evaluates effectiveness of Aspirin in colorectal cancer patients

RTFCCR grant supports ASCOLT study that evaluates effectiveness of Aspirin in colorectal cancer patients

Treatment with antiplatelet therapy does not reduce pain crises in children with sickle cell disease

Treatment with antiplatelet therapy does not reduce pain crises in children with sickle cell disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.